Pediatrix Medical Group Inc (MD) News & EventsMDNews & EventsPediatrix Medical Group Inc

Pediatrix Medical Sees 2026 Adjusted EBITDA of $280M-$300M

Pediatrix Medical sees 2026 adjusted EBITDA $280M-$300M

Company Reports Q2 Revenue of $487.8M, Exceeds Expectations

Reports Q2 revenue $487.8M, consensus $478M. Q2 adjusted EBITDA was $76.4M. "Our strong results this quarter were in line with our expectations and reflect continued favorable trends in the performance of recent acquisitions and same-unit reimbursement metrics," said CEO Mark Ordan. "With a coveted, strong balance sheet, we believe we have exceptional financial flexibility to fund organic growth initiatives while remaining well-positioned to pursue potential high-value strategic opportunities."

Pediatrix Medical Group Confirms Stable Q2 2026 Business Trends

Pediatrix Medical Group provided an update on its second quarter 2026 business trends. In response to recent reports from other healthcare market participants regarding shifting utilization and reimbursement trends, the company confirms that its payor mix for the second quarter remained stable and unchanged relative to recent historical trends and the company's internal expectations. To date, Pediatrix has not experienced the unfavorable payor mix shifts reported elsewhere in the healthcare sector. In addition, Pediatrix has not seen material changes in other net revenue-related trends compared to recent historical periods. Pediatrix reaffirms its previously reported full year 2026 outlook for adjusted EBITDA, and anticipates adjusted EBITDA will be in a range of $280M-$300M.